Valeo Financial Advisors LLC Boosts Stake in Becton, Dickinson and Company $BDX

Valeo Financial Advisors LLC increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 27.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,645 shares of the medical instruments supplier’s stock after purchasing an additional 354 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Becton, Dickinson and Company were worth $283,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Becton, Dickinson and Company by 50.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock worth $18,808,000 after purchasing an additional 27,581 shares during the last quarter. FORA Capital LLC acquired a new position in Becton, Dickinson and Company during the first quarter worth $3,458,000. Foster Victor Wealth Advisors LLC acquired a new position in Becton, Dickinson and Company during the first quarter worth $6,406,000. Finally, GAMMA Investing LLC raised its holdings in Becton, Dickinson and Company by 29.9% during the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock worth $744,000 after purchasing an additional 748 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the company’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president owned 4,887 shares of the company’s stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,023 shares of company stock valued at $562,036 over the last 90 days. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $189.06 on Friday. The firm has a market capitalization of $54.19 billion, a P/E ratio of 34.00, a PEG ratio of 1.51 and a beta of 0.25. The stock has a fifty day moving average price of $189.87 and a 200 day moving average price of $186.61. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm’s revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were paid a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is currently 74.82%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BDX. Royal Bank Of Canada began coverage on Becton, Dickinson and Company in a report on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 price target for the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday. Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Piper Sandler reissued a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.